These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 24170435)

  • 1. Combination treatment of human pancreatic cancer xenograft models with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib and oncolytic herpes simplex virus HF10.
    Yamamura K; Kasuya H; Sahin TT; Tan G; Hotta Y; Tsurumaru N; Fukuda S; Kanda M; Kobayashi D; Tanaka C; Yamada S; Nakayama G; Fujii T; Sugimoto H; Koike M; Nomoto S; Fujiwara M; Tanaka M; Kodera Y
    Ann Surg Oncol; 2014 Feb; 21(2):691-8. PubMed ID: 24170435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncolytic HSV and erlotinib inhibit tumor growth and angiogenesis in a novel malignant peripheral nerve sheath tumor xenograft model.
    Mahller YY; Vaikunth SS; Currier MA; Miller SJ; Ripberger MC; Hsu YH; Mehrian-Shai R; Collins MH; Crombleholme TM; Ratner N; Cripe TP
    Mol Ther; 2007 Feb; 15(2):279-86. PubMed ID: 17235305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.
    Ishida D; Nawa A; Tanino T; Goshima F; Luo CH; Iwaki M; Kajiyama H; Shibata K; Yamamoto E; Ino K; Tsurumi T; Nishiyama Y; Kikkawa F
    Cancer Lett; 2010 Feb; 288(1):17-27. PubMed ID: 19604626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced efficacy of herpes simplex virus mutant HF10 combined with paclitaxel in peritoneal cancer dissemination models.
    Shimoyama S; Goshima F; Teshigahara O; Kasuya H; Kodera Y; Nakao A; Nishiyama Y
    Hepatogastroenterology; 2007 Jun; 54(76):1038-42. PubMed ID: 17629034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncolytic virotherapy with an HSV amplicon vector expressing granulocyte-macrophage colony-stimulating factor using the replication-competent HSV type 1 mutant HF10 as a helper virus.
    Kohno SI; Luo C; Nawa A; Fujimoto Y; Watanabe D; Goshima F; Tsurumi T; Nishiyama Y
    Cancer Gene Ther; 2007 Nov; 14(11):918-26. PubMed ID: 17693992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination therapy of oncolytic herpes simplex virus HF10 and bevacizumab against experimental model of human breast carcinoma xenograft.
    Tan G; Kasuya H; Sahin TT; Yamamura K; Wu Z; Koide Y; Hotta Y; Shikano T; Yamada S; Kanzaki A; Fujii T; Sugimoto H; Nomoto S; Nishikawa Y; Tanaka M; Tsurumaru N; Kuwahara T; Fukuda S; Ichinose T; Kikumori T; Takeda S; Nakao A; Kodera Y
    Int J Cancer; 2015 Apr; 136(7):1718-30. PubMed ID: 25156870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncolytic virotherapy for malignant melanoma with herpes simplex virus type 1 mutant HF10.
    Watanabe D; Goshima F; Mori I; Tamada Y; Matsumoto Y; Nishiyama Y
    J Dermatol Sci; 2008 Jun; 50(3):185-96. PubMed ID: 18226503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncolytic viral therapy for breast cancer with herpes simplex virus type 1 mutant HF 10.
    Teshigahara O; Goshima F; Takao K; Kohno S; Kimata H; Nakao A; Nishiyama Y
    J Surg Oncol; 2004 Jan; 85(1):42-7. PubMed ID: 14696086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suitability of a US3-inactivated HSV mutant (L1BR1) as an oncolytic virus for pancreatic cancer therapy.
    Kasuya H; Nishiyama Y; Nomoto S; Goshima F; Takeda S; Watanabe I; Nomura N; Shikano T; Fujii T; Kanazumi N; Nakao A
    Cancer Gene Ther; 2007 Jun; 14(6):533-42. PubMed ID: 17415379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa).
    Bianco C; Tortora G; Bianco R; Caputo R; Veneziani BM; Caputo R; Damiano V; Troiani T; Fontanini G; Raben D; Pepe S; Bianco AR; Ciardiello F
    Clin Cancer Res; 2002 Oct; 8(10):3250-8. PubMed ID: 12374696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-tumor activity of erlotinib in the BxPC-3 pancreatic cancer cell line.
    Lu YY; Jing DD; Xu M; Wu K; Wang XP
    World J Gastroenterol; 2008 Sep; 14(35):5403-11. PubMed ID: 18803351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erlotinib antitumor activity in non-small cell lung cancer models is independent of HER1 and HER2 overexpression.
    Friess T; Scheuer W; Hasmann M
    Anticancer Res; 2006; 26(5A):3505-12. PubMed ID: 17094474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
    Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
    Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Herpes simplex virus type 1 mutant HF10 oncolytic viral therapy for bladder cancer.
    Kohno S; Luo C; Goshima F; Nishiyama Y; Sata T; Ono Y
    Urology; 2005 Nov; 66(5):1116-21. PubMed ID: 16286150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of cholangiocarcinoma with oncolytic herpes simplex virus combined with external beam radiation therapy.
    Jarnagin WR; Zager JS; Hezel M; Stanziale SF; Adusumilli PS; Gonen M; Ebright MI; Culliford A; Gusani NJ; Fong Y
    Cancer Gene Ther; 2006 Mar; 13(3):326-34. PubMed ID: 16138120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of the tumor angiogenesis inhibitor bevacizumab and intratumoral oncolytic herpes virus injections as a treatment strategy for human gastric cancers.
    Deguchi T; Shikano T; Kasuya H; Nawa A; Fujiwara S; Takeda S; Gewen T; Sahin TT; Yamada S; Kanzaki A; Yamamura K; Fujii T; Sugimoto H; Nomoto S; Fukuda S; Nishikawa Y; Kodera Y; Nakao A
    Hepatogastroenterology; 2012 Sep; 59(118):1844-50. PubMed ID: 22172413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An armed oncolytic herpes simplex virus expressing thrombospondin-1 has an enhanced in vivo antitumor effect against human gastric cancer.
    Tsuji T; Nakamori M; Iwahashi M; Nakamura M; Ojima T; Iida T; Katsuda M; Hayata K; Ino Y; Todo T; Yamaue H
    Int J Cancer; 2013 Jan; 132(2):485-94. PubMed ID: 22729516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.
    Ciardiello F; Caputo R; Bianco R; Damiano V; Fontanini G; Cuccato S; De Placido S; Bianco AR; Tortora G
    Clin Cancer Res; 2001 May; 7(5):1459-65. PubMed ID: 11350918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pilot study of oncolytic viral therapy using mutant herpes simplex virus (HF10) against recurrent metastatic breast cancer.
    Kimata H; Imai T; Kikumori T; Teshigahara O; Nagasaka T; Goshima F; Nishiyama Y; Nakao A
    Ann Surg Oncol; 2006 Aug; 13(8):1078-84. PubMed ID: 16865590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.